| Date | Title | Description |
| 22.04.2026 | Achieve Life Sciences: Up To $354 Million Private Placement Funds Cytisinicline Development And Commercialization | Achieve Life Sciences announced it has entered into a securities purchase agreement for a private placement that could generate up to $354 million in gross proceeds, including $180 million upfront and up to an additional $174 million tied t... |
| 14.01.2026 | Caldera Therapeutics Launches With $112.5 Million And Doses First Subjects In Phase 1 Trial Of CLD-423 | Caldera Therapeutics, a clinical-stage biotechnology company developing a first-in-class bispecific antibody for inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases, launched with $112.5 million in total capital... |
| 14.01.2026 | Caldera Therapeutics Launches with $112.5M in Total Capital | Caldera Therapeutics, Inc., a Cambridge, MA-based clinical stage biotechnology company, launched with $112.5M total capital raised.
The amount consisted of a $75M Series A round from Atlas Venture, LAV and venBio, and most recently a $37.5M... |
| 11.01.2026 | Parabilis Medicines Secures $305 Million for Cancer Drug Revolution | Parabilis Medicines recently closed an oversubscribed $305 million Series F financing round. This substantial capital propels its lead cancer candidate, zolucatetide, towards pivotal clinical trials for desmoid tumors and other challenging ... |
| 08.01.2026 | Parabilis Medicines: $305 Million Series F Raised To Advance Zolucatetide Program And Helicon Peptide Platform | Parabilis Medicines, a clinical-stage cancer drug developer, said it has closed an oversubscribed $305 million Series F financing to fund ongoing clinical development of its lead candidate FOG-001 (zolucatetide) across multiple tumor types ... |
| 08.01.2026 | Parabilis Medicines Raises $305M Series F Funding | Parabilis Medicines, a Cambridge, MA-based clinical-stage biopharmaceutical company committed to creating medicines for people living with cancer, closed a $305m Series F financing.
The round was co-led by RA Capital Management, Fidelity Ma... |
| 08.01.2026 | Parabilis rockets ahead with $305M series F to 'upend the status quo' with tumor drug | Parabilis Medicines is taking an early lead in the 2026 biotech fundraising race, closing a $305 million series F round that will fuel a pivotal push for its potential first-in-class cancer drug.
The funds come from a smorgasbord of existin... |
| 28.12.2025 | Aeovian Pharmaceuticals Secures $55M Series B for Groundbreaking Epilepsy Treatment | Aeovian Pharmaceuticals secured a significant $55 million Series B funding. This pivotal investment propels its lead candidate, AV078, into a Phase 2 study. AV078 is a first-in-class CNS-penetrant selective mTORC1 inhibitor. It targets seve... |
| 27.12.2025 | Aeovian Pharmaceuticals: $55 Million Series B Raised To Advance AV078 For Tuberous Sclerosis Complex-Related Refractory Epilepsy | Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company based in Berkeley, California, has closed an oversubscribed $55 million Series B financing to support completion of a Phase 2 proof-of-concept study for its lead candidate,... |
| 16.12.2025 | Aeovian Pharmaceuticals Raises $55M in Funding | Aeovian Pharmaceuticals, a Berkeley, CA-based clinical-stage biopharmaceutical company, raised $55M in funding.
The round was led by Luma Group and CTI Life Sciences Fund, with participation from Foresite Capital, SymBiosis, the TSC Allianc... |
| 23.07.2025 | Sanofi to Acquire Vicebio, for US$1.6 Billion | Sanofi (EURONEXT: SAN and NASDAQ: SNY), a Paris, France-based AI-powered biopharma company, acquired Vicebio, a London, UK-based biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, for ... |
| 08.08.2024 | venBio's $528 Million Leap into Life Sciences | In the world of venture capital, timing is everything. venBio has just hit a home run with the closing of its fifth fund, venBio Global Strategic Fund V. This new fund has amassed over $528 million in capital commitments, surpassing its ini... |
| 07.08.2024 | venBio Reveals $528 Million Global Strategic Fund V | venBio announced the closing of venBio Global Strategic Fund V, which is its fifth life sciences venture capital fund, exceeding its target and closing on about $528 million in capital commitments in an oversubscribed fundraise. And the fir... |
| 05.08.2024 | venBio Raises $528M for Fifth Life Sciences Fund | What You Should Know:
– venBio, a leading life sciences venture capital firm, announced the successful closing of its fifth fund, venBio Fund V, with over $528M in capital commitments.
– The new fund will focus on investing in biopharmaceut... |
| 26.06.2023 | Pharvaris obtains $70 million in a private placement round | |
| 04.06.2021 | StartUPDATES: New developments for healthcare startups | Stellar Health is pleased to announce the appointment of JoRel Nye, former Senior Vice President of Technical Product Management at Aledade as its new Chief Product Officer.
Stellar Health is a point-of-care, cloud-based platform that helps... |
| 04.06.2021 | venBio Closes Venture Capital Fund Focused on Life Sciences, At $550M | venBio, a Palo Alto, CA and San Francisco, CA-based closed its fourth life sciences venture capital fund, venBio Global Strategic Fund IV, LP, at approximately $550m.
The capital was raised from existing and new investors, including a broad... |
| 03.06.2021 | Salesforce wants to battle Microsoft. But will it get Slack right? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Late last year, Salesforce threw down a weighty gauntlet to Microsoft’s work-from-home Teams soft... |
| 19.11.2020 | Pharvaris Announces $80 Million Series C Financing | |
| 19.11.2020 | Pharvaris Announces $80 Million Series C Financing | Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic condition with symptoms that include episodes of debilitating and often painful swelling in the hands, feet, face (lips and tongue), gastrointestinal tract, urog... |
| 06.04.2020 | venBio closes third fund for biopharma startup investment, valued at $394M | “We remain committed to our founding strategy at venBio, namely to turn great science into impactful medicine,” said Corey Goodman, one of three managing partners of the fund, in a statement. “Our investment thesis, regardless of stage of c... |
| 03.04.2020 | venBio Closes Life Sciences Venture Capital Fund, at $394M | venBio Partners, a San Francisco, and Palo Alto, CA-based life sciences venture capital firm, closed its third fund, at approximately $394m.
venBio Global Strategic Fund III was raised from existing and new investors, including a broad rang... |
| 25.06.2018 | Akero Therapeutics Closes $65 Million Series A | Akero Therapeutics, Inc., a biotechnology company focused on transforming the treatment of non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases, today announced the completion of a $65 million Series A financing. The fi... |
| 04.01.2018 | Neurogastrx Raises $45M Series A | Neurogastrx, Inc., a private biopharmaceutical company focused on discovering and developing therapies for gastrointestinal disorders affecting the enteric nervous system, today announced a transformative $45M Series A financing co-led by 5... |
| 18.07.2017 | F-Prime Capital Joins $50M Series C for Menlo Therapeutics | Menlo Therapeutics Inc. announced today that the company has raised $50M to advance development of serlopitant, a novel NK-1 receptor antagonist, as a once-daily oral treatment for pruritus (itch) associated with atopic dermatitis, psoriasi... |
| 18.07.2017 | Rock Springs Capital Joins $50M Series C for Menlo Therapeutics | Menlo Therapeutics Inc. announced today that the company has raised $50M to advance development of serlopitant, a novel NK-1 receptor antagonist, as a once-daily oral treatment for pruritus (itch) associated with atopic dermatitis, psoriasi... |
| 05.05.2017 | A $2B oncology deal goes bust at the hands of an activist investor | But behind the scenes, venBio wasn’t having any of it. The group moved quickly to get a 30-day hold on the agreement, arguing that it was not in the best interests of Immunomedics’ shareholders.
“We announced the deal and very soon after th... |
| 03.12.2016 | Impel NeuroPharma raises $36M for drug delivery platform that bypasses blood-brain barrier | Impel NeuroPharma co-founder and CEO John Hoekman. (Impel NeuroPharma Photo)
Impel NeuroPharma, a Seattle-based biotechnology and pharmaceutical company, announced a $36 million Series C round to develop neurological drugs and an accompanyi... |
| 06.05.2016 | venBio Partners Closes Second Life Sciences Venture Capital Fund, at $315M | venBio Partners LLC, a global life sciences investment firm, closed its second venture capital fund, at approximately $315m.
Anchored by major investments from three strategic limited partners – Amgen, Merck, and Baxalta – along with a grou... |
| 06.05.2016 |
Amgen Backs New $315M Life Sciences Fund
| Thousand Oaks-based Amgen has helped to back a new, life sciences fund, managed by San Francisco-based venBio, as an anchor supporter of a new fund. venBio said Friday that it has closed a $315M life sciences fund, venBio Global Strategic F... |
| 22.03.2016 | VenBio Raises $288M for Second Venture Capital Fund | VenBio, LLC, a bi-coastal healthcare venture capital firm, raised $288m for its second fund.
According to a regulatory filing with the SEC, venBio Global Strategic Fund II L.P. has a final target of $303m with $15m remained to be raised.
Th... |
| 30.12.2015 | Solstice Biologics raises $4M – but where did CEO Lou Tartaglia go? | But Lou Tartaglia, a former partner at Boston-based Third Rock Ventures with a long history in successful startup launch, joined Solstice in June 2014 – an indication that the broader investment community stood behind the company’s RNAi sci... |
| 12.08.2015 | Checkmate nets $20M to develop drug that boosts checkpoint inhibitor efficacy | Checkmate Pharmaceuticals operates on the idea that checkpoint inhibitor therapies would be much more effective if they were combined with an agent that could stimulate a person’s immune response. So, on top of the new financing, it’s also ... |
| 12.08.2015 | Daily funding roundup - August 12, 2015 | PokitDoc closed $34M; Infogain secured $63M; Soothe raised $10.6M
If there's a service that I often book with little time in advance, it's getting a massage. It's hard to predict when you're neck or back will ache, and when you have a free ... |
| 27.07.2015 | Daily funding roundup - July 27, 2015 | Palantir received $450M; DraftKings added $300M; Secret Escapes bagged $60M
Buyatab Online Inc., a Vancouver, BC, Canada-based international provider of digital gift card solutions, completed a funding round of undisclosed amount. Backers w... |
| 04.10.2012 | Aragon Pharmaceuticals Raises $50M in Series D Financing | Aragon Pharmaceuticals Inc., a San Diego, California-based developer of 2nd generation anti-hormonal agents for hormone-driven cancers, has raised $50m in a Series D financing.
The round was led by venBio, with participation from existing i... |
| 04.10.2012 | Aragon Pharmaceuticals Inks $50M Series D |
SAN DIEGO, CA, Aragon raised $50 million in a Series D financing to advance the company's pipeline of therapies targeting hormone-driven cancers.
>> Click here for more funding data on Aragon Pharmaceuticals
>> To export Ara... |
| 26.01.2010 | A new model for life-sciences venture firms? MedCity Morning Read, Jan. 26, 2010 | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermin... |
| - | Solstice Biologics raises $4M – but where did CEO Lou Tartaglia go? | Looks like Solstice Biologics, the tumultuous San Diego biotech that’s developing some promising RNAi therapeutics, continues its rocky gait – it appears to be sans a CEO.
Through a regulatory filing, we learn it’s just raised a small cache... |
| - | StartUPDATES: New developments for healthcare startups | Stellar Health is pleased to announce the appointment of JoRel Nye, former Senior Vice President of Technical Product Management at Aledade as its new Chief Product Officer.
Stellar Health is a point-of-care, cloud-based platform that helps... |
| - | A new model for life-sciences venture firms? MedCity Morning Read, Jan. 26, 2010 | Highlights of the important and the interesting from the world of health care:
A new model for life-sciences venture firms? Could a new investment company made of veterans from MPM Capital, OrbiMed Advisors, Pfizer Inc. and Morgan Stanley s... |
| - | A $2B oncology deal goes bust at the hands of an activist investor | Activist investor venBio had a good Friday. Seattle Genetics and Immunomedics did not. The two latter companies agreed to fold on their $2 billion oncology deal, while Immunomedics’ CEO and CSO also forfeited their jobs.
First announced in ... |
| - | Checkmate nets $20M to develop drug that boosts checkpoint inhibitor efficacy | The name of the company’s pretty pithy: Checkmate Pharmaceuticals, so-called because its drug in development serves as a “mate” to checkpoint inhibitors, enhancing their efficacy.
The Cambridge company just launched with a $20 million Serie... |
| - | venBio closes third fund for biopharma startup investment, valued at $394M | A venture capital firm focused on life sciences has closed a fund worth nearly $400 million that it plans to use to invest in biopharmaceutical companies.
San Francisco-based venBio Partners said Friday that it had closed its venBio Global ... |